Copyright Reports & Markets. All rights reserved.

Global Oncolytic Virus Therapy Market Size, Status and Forecast 2019-2025

Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Oncolytic Virus Therapy Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 HSV-based Oncolytic Viruses
      • 1.4.3 Adenoviruses-based Oncolytic Viruses
      • 1.4.4 Vaccinia Virus-based Oncolytic Viruses
      • 1.4.5 Vesicular Stomatitis Virus-based Oncolytic Viruses
      • 1.4.6 Newcastle Disease Virus-based Oncolytic Viruses
    • 1.5 Market by Application
      • 1.5.1 Global Oncolytic Virus Therapy Market Share by Application (2014-2025)
      • 1.5.2 Melanoma
      • 1.5.3 Prostate Cancer
      • 1.5.4 Breast Cancer
      • 1.5.5 Ovarian Cancer
      • 1.5.6 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Oncolytic Virus Therapy Market Size
    • 2.2 Oncolytic Virus Therapy Growth Trends by Regions
      • 2.2.1 Oncolytic Virus Therapy Market Size by Regions (2014-2025)
      • 2.2.2 Oncolytic Virus Therapy Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Oncolytic Virus Therapy Market Size by Manufacturers
      • 3.1.1 Global Oncolytic Virus Therapy Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Oncolytic Virus Therapy Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Oncolytic Virus Therapy Market Concentration Ratio (CR5 and HHI)
    • 3.2 Oncolytic Virus Therapy Key Players Head office and Area Served
    • 3.3 Key Players Oncolytic Virus Therapy Product/Solution/Service
    • 3.4 Date of Enter into Oncolytic Virus Therapy Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Oncolytic Virus Therapy Market Size by Type (2014-2019)
    • 4.2 Global Oncolytic Virus Therapy Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Oncolytic Virus Therapy Market Size (2014-2019)
    • 5.2 Oncolytic Virus Therapy Key Players in United States
    • 5.3 United States Oncolytic Virus Therapy Market Size by Type
    • 5.4 United States Oncolytic Virus Therapy Market Size by Application

    6 Europe

    • 6.1 Europe Oncolytic Virus Therapy Market Size (2014-2019)
    • 6.2 Oncolytic Virus Therapy Key Players in Europe
    • 6.3 Europe Oncolytic Virus Therapy Market Size by Type
    • 6.4 Europe Oncolytic Virus Therapy Market Size by Application

    7 China

    • 7.1 China Oncolytic Virus Therapy Market Size (2014-2019)
    • 7.2 Oncolytic Virus Therapy Key Players in China
    • 7.3 China Oncolytic Virus Therapy Market Size by Type
    • 7.4 China Oncolytic Virus Therapy Market Size by Application

    8 Japan

    • 8.1 Japan Oncolytic Virus Therapy Market Size (2014-2019)
    • 8.2 Oncolytic Virus Therapy Key Players in Japan
    • 8.3 Japan Oncolytic Virus Therapy Market Size by Type
    • 8.4 Japan Oncolytic Virus Therapy Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Oncolytic Virus Therapy Market Size (2014-2019)
    • 9.2 Oncolytic Virus Therapy Key Players in Southeast Asia
    • 9.3 Southeast Asia Oncolytic Virus Therapy Market Size by Type
    • 9.4 Southeast Asia Oncolytic Virus Therapy Market Size by Application

    10 India

    • 10.1 India Oncolytic Virus Therapy Market Size (2014-2019)
    • 10.2 Oncolytic Virus Therapy Key Players in India
    • 10.3 India Oncolytic Virus Therapy Market Size by Type
    • 10.4 India Oncolytic Virus Therapy Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Oncolytic Virus Therapy Market Size (2014-2019)
    • 11.2 Oncolytic Virus Therapy Key Players in Central & South America
    • 11.3 Central & South America Oncolytic Virus Therapy Market Size by Type
    • 11.4 Central & South America Oncolytic Virus Therapy Market Size by Application

    12 International Players Profiles

    • 12.1 Amgen
      • 12.1.1 Amgen Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Oncolytic Virus Therapy Introduction
      • 12.1.4 Amgen Revenue in Oncolytic Virus Therapy Business (2014-2019)
      • 12.1.5 Amgen Recent Development
    • 12.2 Oncolytics Biotech
      • 12.2.1 Oncolytics Biotech Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Oncolytic Virus Therapy Introduction
      • 12.2.4 Oncolytics Biotech Revenue in Oncolytic Virus Therapy Business (2014-2019)
      • 12.2.5 Oncolytics Biotech Recent Development
    • 12.3 Viralytics
      • 12.3.1 Viralytics Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Oncolytic Virus Therapy Introduction
      • 12.3.4 Viralytics Revenue in Oncolytic Virus Therapy Business (2014-2019)
      • 12.3.5 Viralytics Recent Development
    • 12.4 Transgene SA
      • 12.4.1 Transgene SA Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Oncolytic Virus Therapy Introduction
      • 12.4.4 Transgene SA Revenue in Oncolytic Virus Therapy Business (2014-2019)
      • 12.4.5 Transgene SA Recent Development
    • 12.5 Oncolys BioPharma
      • 12.5.1 Oncolys BioPharma Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Oncolytic Virus Therapy Introduction
      • 12.5.4 Oncolys BioPharma Revenue in Oncolytic Virus Therapy Business (2014-2019)
      • 12.5.5 Oncolys BioPharma Recent Development
    • 12.6 Targovax
      • 12.6.1 Targovax Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Oncolytic Virus Therapy Introduction
      • 12.6.4 Targovax Revenue in Oncolytic Virus Therapy Business (2014-2019)
      • 12.6.5 Targovax Recent Development
    • 12.7 PsiOxus Therapeutics
      • 12.7.1 PsiOxus Therapeutics Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Oncolytic Virus Therapy Introduction
      • 12.7.4 PsiOxus Therapeutics Revenue in Oncolytic Virus Therapy Business (2014-2019)
      • 12.7.5 PsiOxus Therapeutics Recent Development
    • 12.8 SillaJen Biotherapeutics
      • 12.8.1 SillaJen Biotherapeutics Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Oncolytic Virus Therapy Introduction
      • 12.8.4 SillaJen Biotherapeutics Revenue in Oncolytic Virus Therapy Business (2014-2019)
      • 12.8.5 SillaJen Biotherapeutics Recent Development
    • 12.9 Sorrento Therapeutics
      • 12.9.1 Sorrento Therapeutics Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Oncolytic Virus Therapy Introduction
      • 12.9.4 Sorrento Therapeutics Revenue in Oncolytic Virus Therapy Business (2014-2019)
      • 12.9.5 Sorrento Therapeutics Recent Development
    • 12.10 Lokon Pharma
      • 12.10.1 Lokon Pharma Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Oncolytic Virus Therapy Introduction
      • 12.10.4 Lokon Pharma Revenue in Oncolytic Virus Therapy Business (2014-2019)
      • 12.10.5 Lokon Pharma Recent Development
    • 12.11 Genelux Corporation
    • 12.12 Vyriad
    • 12.13 TILT Biotherapeutics
    • 12.14 Cold Genesys

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
      Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
      The application of oncolytic virus therapy includes melanoma, prostate cancer, breast cancer, ovarian cancer and others, and the proportion of R&D Investment for melanoma in 2017 is about 34%.
      Market competition is intense. Amgen, Oncolytics Biotech, Viralytics, Transgene SA are the leading developers in the industry; with high investment in research marketing and they will monopoly position in the industry.
      In 2018, the global Oncolytic Virus Therapy market size was 2 million US$ and it is expected to reach 14 million US$ by the end of 2025, with a CAGR of 24.9% during 2019-2025.

      This report focuses on the global Oncolytic Virus Therapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Oncolytic Virus Therapy development in United States, Europe and China.

      The key players covered in this study
      Amgen
      Oncolytics Biotech
      Viralytics
      Transgene SA
      Oncolys BioPharma
      Targovax
      PsiOxus Therapeutics
      SillaJen Biotherapeutics
      Sorrento Therapeutics
      Lokon Pharma
      Genelux Corporation
      Vyriad
      TILT Biotherapeutics
      Cold Genesys

      Market segment by Type, the product can be split into
      HSV-based Oncolytic Viruses
      Adenoviruses-based Oncolytic Viruses
      Vaccinia Virus-based Oncolytic Viruses
      Vesicular Stomatitis Virus-based Oncolytic Viruses
      Newcastle Disease Virus-based Oncolytic Viruses

      Market segment by Application, split into
      Melanoma
      Prostate Cancer
      Breast Cancer
      Ovarian Cancer 
      Others

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Oncolytic Virus Therapy status, future forecast, growth opportunity, key market and key players.
      To present the Oncolytic Virus Therapy development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Oncolytic Virus Therapy are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now